Galvanize raises $130M Series D led by HealthQuest for PEF ablation
TLDR
- Galvanize Therapeutics, a pulsed electric field ablation device maker, closed a $130M Series D led by HealthQuest Capital.12
- Olympus Innovation Ventures and Braidwell LP joined as new investors; the company did not disclose valuation or revenue.1
- The FDA clearance is for soft-tissue ablation, not a named disease; procedure counts and clinical claims are company-reported.1
Galvanize Therapeutics, a Redwood City, California company developing pulsed electric field (PEF) ablation technology for oncology and chronic disease, announced on 16 November the closing of an "oversubscribed $130 million Series D financing".1 HealthQuest Capital, which the release describes as "a growth equity firm focused on commercial-stage healthcare companies", led the round, with Olympus Innovation Ventures and Braidwell LP joining as new investors.1 Existing investors including Sofinnova Partners, Norwest, Fidelity Management & Research Company and T. Rowe Price Associates also took part, and HealthQuest founder Garheng Kong will join the board.1 MassDevice and Axios Pro Rata report the same lead and investors.23 Galvanize did not disclose a valuation, revenue or any investor's cheque size.1
The company says the money will fund commercial expansion of its Aliya PEF system, clinical evidence, development of RheOx therapy for chronic bronchitis, and next-generation PEF products.1 Aliya is 510(k) cleared in the United States for "surgical ablation of soft tissue", is not commercially available elsewhere, and is "not intended to treat, cure, prevent, or mitigate any specific disease or condition", while RheOx remains investigational in the US.1 According to the company, it has passed 4,000 procedures, enrolled more than 300 patients in its PROPEL registry and cites more than 40 peer-reviewed PEF publications.1 In May it said its Aliya EX generator gives up to a 2x larger ablation diameter and as much as a 7x increase in ablation volume than the previous generation, which are company figures.4
The round follows a $100M Series C in September 2025, which MedTech Dive reports was led by Sofinnova Partners.5 Fierce Biotech reported that the Series C coincided with Doug Godshall, previously chief executive of Shockwave Medical and HeartWare International, becoming chief executive; the Series D release lists him as chairman and chief executive.61
Independent evidence is early. Scienmag, summarising a five-patient University of Kansas Medical Center case series in CVIR Oncology, reports that clinicians using the Aliya System saw tumour growth in three patients and stability in one, and that one patient died before follow-up imaging.7 A narrative review in the Journal of Thoracic Disease covered 11 studies and 249 patients given PEF for non-small cell lung cancer, found responses heterogeneous, and said randomised controlled trials are needed; its abstract addresses PEF in general and does not name Aliya.8
The competitive picture is mostly adjacent. Pulsed field ablation is established in cardiology, where MassDevice names Medtronic, Boston Scientific, Johnson & Johnson MedTech, Abbott and Kardium; it adds that Pulse Biosciences, whose percutaneous soft-tissue electrode the FDA cleared in 2025, said in March 2026 it would centre resources on a cardiac catheter programme.9 None of the sources says these companies target Galvanize's lung and soft-tissue niche directly.
The release says HealthQuest has approximately $2bn in committed capital.1 Its recent medtech deals include leading OrganOx's $142M financing in February 2025 and co-leading Alpheus Medical's $52M Series B in May 2025 with Samsara BioCapital.1011 Olympus Innovation Ventures is Olympus's corporate venture fund; MassDevice reported in December 2025 that its second fund holds $150M and targets gastrointestinal, urology and respiratory technologies.12 Galvanize's release does not say why Olympus invested.
Why it matters: a $130M Series D led by a growth-equity firm shows continued investor appetite for PEF ablation beyond cardiac use, but the clearance is for soft-tissue ablation rather than a named disease, and usage and clinical claims remain company-reported with early independent evidence.178
Sources
- Galvanize Therapeutics Raises $130 Million in Oversubscribed Series D Financing to Accelerate Commercial Growth and Advance PEF Innovation (PR Newswire (Galvanize Therapeutics))
- Galvanize Therapeutics raises $130M in Series D funding round for pulsed electric field tech (MassDevice)
- Galvanize's $130M haul, $110M for self-improving AI, Focus Financial's new backer (Axios Pro Rata)
- Galvanize Therapeutics Receives FDA Clearance for Aliya EX Generator, Expanding its Aliya Pulsed Electric Field Portfolio for Surgical Ablation of Soft Tissue (PR Newswire (Galvanize Therapeutics))
- Pulse wins IDE approval; Galvanize pulls in $100M (MedTech Dive)
- Galvanize Therapeutics nets $100M, and a new CEO, to bring pulsed field ablation to lung cancer (Fierce Biotech)
- Electric Pulse Therapy Shows Disappointing Results for Lung Cancer (Scienmag)
- The role of pulsed electric field therapy in non-small cell lung cancer: a narrative review of a novel minimally invasive intervention (Journal of Thoracic Disease)
- Pulse Biosciences shifts focus toward cardiac PFA program (MassDevice)
- OrganOx Raises $142M Financing Led by HealthQuest Capital (Orsco Lifesciences (OrganOx release))
- Alpheus Medical raises $52M for ultrasound-activated therapy (MassDevice)
- Olympus launches second medtech investment fund with $150M (MassDevice)